European Medicines Agency opens public discussion on need for active control in clinical trials
The European Medicines Agency (EMA) has published a reflection paper on the need for active control in therapeutic areas where use of a placebo is deemed ethical and one or more established medicines are available. The reflection paper is open for public consultation until 31 March 2011.
The paper outlines a framework for the discussion and justification of the choice of control arms that is expected from an applicant in a centralised marketing authorisation application.
How useful is this page?
Average rating:Based on 0 ratings
Add your rating:
- See all ratings
0 ratings0 ratings0 ratings0 ratings0 ratings
Comments should be sent to firstname.lastname@example.org using the template.